Fit-for-purpose pharmacogenomic biomarkers in drug development: a project team case study with ‘what-ifs’

Over the past four years, the annual US FDA–DIA pharmacogenomic workshops have brought together attendees with wide-ranging expertise spanning industry, regulatory authorities and academia. This special report summarizes a breakout session using a novel, interactive case format as a way to engage participants, raise awareness and share diverse learnings via ‘real life’ decisions that project teams might face in developing a new medicine. This case was situated just prior to approval by a Regulatory Authority as a project team is finalizing a new medicine label. To effectively integrate new biomarkers such as pharmacogenomics into developing new medicines, this session highlighted...

To view this content, please register now for access

It's completely free